logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Gastro-oesophageal reflux disease in primary care : an international study of different treatment strategies with omeprazole.

    Article - En anglais

    Objective To assess the efficacy of omeprazole in patients presenting with troublesome reflux symptoms.

    Design Randomized, double-blind, parallel-group, placebo-controlled comparison.

    Setting Primary care.

    Subjects Patients were recruited using a symptom-based questionnaire for diagnosis of gastro-oesophageal reflux disease.

    Interventions After endoscopy, patients without endoscopic oesophagitis were randomized to omeprazole 20 mg (Ome20), omeprazole 10 mg (Ome10) or placebo once daily for 4 weeks (n=261) and those with oesophagitis (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n=277).

    Patients not symptom-free at 4 weeks received open treatment with Ome20 once daily for a further 4 weeks.

    Those symptom-free at 4-8 weeks were followed up for 6 months off treatment, to see whether their symptoms recurred.

    Main outcome measure Complete upper GI symptom relief during week 4 on Ome20 or Ome10 in patients with or without endoscopic oesophagitis.

    Results Forty one percent of all patients on Ome20 and 35% on Ome10 reported complete relief from upper GI symptoms during week 4, whilst 73% of the patients on Ome20 and 62% on Ome10 obtained sufficient control.

    Complete relief during week 4 was reported by 19% of endoscopy-negative patients on placebo, and sufficient control by 35%. Endoscopic healing at 4 weeks occurred in 76% of oesophagitis patients on Ome20 and in 56% on Ome10. (...)

    Mots-clés Pascal : Reflux gastrooesophagien, Symptomatologie, Diagnostic, Soin santé primaire, Questionnaire, Traitement, Chimiothérapie, Antisécrétoire, Oméprazole, Optimisation, Dosage, Etude comparative, Homme, Appareil digestif pathologie, Oesophage pathologie

    Mots-clés Pascal anglais : Gastroesophageal reflux, Symptomatology, Diagnosis, Primary health care, Questionnaire, Treatment, Chemotherapy, Antisecretory agent, Omeprazole, Optimization, Assay, Comparative study, Human, Digestive diseases, Esophageal disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0177513

    Code Inist : 002B13A03. Création : 11/09/1998.